Venous thromboembolism prevention in acutely III nonsurgical patients

Annals of Pharmacotherapy

Volumn 39, Issue 7-8, 2005, Pages 1318-1324

  Brophy, Donald F ^a   Dougherty, John A ^b,c   Garrelts, James C ^d   Parish, Roy C ^e   Rivey, Michael P ^f,g   Stumpf, Janice L ^h,i   Taylor, Charles T ^j   Mathis, A Scott ^k,l  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b ORLANDO REGIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

^d WESLEY MEDICAL CENTER   (United States)

^e SOUTHERN UNIVERSITY   (United States)

^f UNIVERSITY OF MONTANA   (United States)

^g Department of Obstetrics Gynecology   (United States)

^h Mininstry of Health   (Italy)

ⁱ UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^j ST LOUIS COLLEGE OF PHARMACY   (United States)

^k RUTGERS UNIVERSITY   (United States)

^l SAINT BARNABAS MEDICAL CENTER   (United States)

more..

Author keywords

Anticoagulants: Fondaparinux, heparin, low molecular weight heparin; Deep vein thrombosis; Prophylaxis

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; WARFARIN;

ACUTE DISEASE; ADULT; AWARENESS; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INTRAOCULAR HEMORRHAGE; KIDNEY FUNCTION; MALE; MEDICAL DECISION MAKING; META ANALYSIS; MONOTHERAPY; PATIENT CARE; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; REVIEW; RISK ASSESSMENT; SPINAL CORD HEMORRHAGE; SYSTEMATIC REVIEW; TECHNIQUE; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; ANTICOAGULANTS; CLINICAL TRIALS; HOSPITALIZATION; HUMANS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM;

EID: 21744453501     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G127     Document Type: Review

References (27)

1. Goldhaber SZ, Tapson VF, for the Deep Vein Thrombosis (DVT) FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004;93:259-62. DOI 10.1016/j.amjcard.2003. 09.057
2. Geerts W, Pineo G, Heit J, Bergqvist D, Lassen M, Colwell C. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):338S-400S.
3. Deitelzweig S, Groce JB. Anticoagulant prophylaxis in medical patients: an objective assessment. Pharmacotherapy 2004;24(8 pt 2):120S-6S.
4. Dunn P, Hill CD. Joint Commission, National Quality Forum to work on deep vein thrombosis prevention and care project, www.jcaho.org/ news+room/news+release+archives/jcaho_092704.htm (accessed 2005 Feb 3).
5. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al., for the Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800.
6. Leizorovicz A, Cohen AT, Turpie AGG, Olsson CG, Vaitkus PT, Goldhaber SZ, for the PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-9. DOI 10.1161/01.CIR.0000138928.83266.24
7. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Tomkowski W, Turpei AGG, et al. Fondaparinux for the prevention of VTE in acutely ill medical patients (abstract 42). Blood 2003;102:15a.
8. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, for THE-PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003;145:614-21. DOI 10.1067/mhj.2003.189
9. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000;83:14-9.
10. Joffe HV, Kucher N, Tapson VF, Goldhaber SZ, for the Deep Vein Thrombosis (DVT) FREE Steering Committee. Upper-extremity deep vein thrombosis. A prospective registry of 592 patients. Circulation 2004;110:1605-11. DOI 10.1161/01.CIR.0000142289.94369.D7
11. Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical patients: validation of a thrombosis risk score. J Thromb Haemostas 2004;2:2156-61.
12. Labarere J, Bosson JL, Brion JP, Fabre M, Imbert B, Carpentier P, et al. Validation of a clinical guideline on prevention of venous thromboembolism in medical inpatients: a before-and-after study with systematic ultrasound examination. J Intern Med 2004;256:338-48.
13. Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005;352:969-77.
14. Ibrahim EH, Iregui M, Prentice D, Sherman G, Kollef MH, Shannon W, Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. Crit Care Med 2002;30:771-4.
15. DeShong D, Mathis AS. Lack of effect of educational interventions in changing the pattern of VTE prophylaxis (abstract RP-391). Presented at: American Society of Health-System Pharmacists 2004 Midyear Clinical Meeting, Orlando, FL, December 5-9, 2004.
16. Casserly LF, Dember LM. Thrombosis in end-stage renal disease. Semin Dial 2003;16:245-56.
17. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. Arch Pathol Lab Med 1998;122:799-807.
18. Brophy DF, Martin EJ, Gehr TW, Carr ME Jr. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. Am J Kidney Dis 2004;44:270-7. DOI 10.1053/j.ajkd.2004.04.032
19. Brophy DF, Martin EJ, Best AM, Gehr TW, Carr ME. Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction. J Thromb Haemost 2004;2:1299-304.
20. Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002;105:225-31.
21. Package insert. Lovenox (enoxaparin). Bridgewater, NJ: Avertis Pharmaceuticals, July 2004.
22. Package insert. Fragmin (dalteparin). Kalamazoo, MI: Pharmacia and Upjohn, March 2004.
23. Package insert. Arixtra (fondaparinux). Research Triangle Park, NC: GlaxoSmithKline, September 2004.
24. Sanderink GJ, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shukla U, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002;72:308-18. DOI 10.1067/mcp.2002.127114
25. Spinier SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM; ESSENCE and TMI 11B Investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003;146:33-41. DOI 10.1016/S0002-8703(03)00121-2
26. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002;12:19-24. DOI 10.1381/096089202321144522
27. Guyatt G, Schunemann HJ, Cook D, Jaeschke R, Pauker S. Applying the grades of recommendation for antithrombotic and thrombolytic therapy. Chest 2004;126(suppl):179S-87S.